The Future Of Rebates: MedPAC Will Be Watching For Pricing Law Impacts

The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on actual prescription drug spending – but immediate recommendations may not be viable given the changes coming from implementation of the Inflation Reduction Act.

pharma seesaw
• Source: Shutterstock

The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on drug pricing in the Part D pharmacy benefit program – but will have to adopt a wait-and-see approach to recommending new policies given the expected impact of the Inflation Reduction Act.

MedPAC, which is chartered by Congress to provide recommendations to improve the Medicare program, heard an analysis of some...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access